|
Media Releases |
Financial Reports |
Presen-tations |
|
04/19/2007
|
|
|
|
| Basel, April 19, 2007 – Lonza, the global life sciences company, announces the groundbreaking plans for the expansion of its Portsmouth, N.H. (USA) mammalian biopharmaceutical manufacturing facility. |
Following the start of construction of Lonza’s second large-scale mammalian facility in Singapore which took place at the end of March 2007, the expansion continues. On May 17th 2007, the groundbreaking will take place for a 330,000 square foot facility designed to house leading edge biotherapeutics manufacturing technologies as well as offices, warehouse and support systems. The facility is being designed specifically with new high titre processes in mind.
The expansion may result in as many as 350 additional jobs in Portsmouth once fully built-out and undersigned by customers. The number of commercial and clinical biotherapeutics manufactured at the site to support Lonza’s customer base will also increase. The investment amount is anticipated to be in the region of $300 million, depending on detailed design, which is dependent upon specific customer projects.
The Portsmouth site is the largest scale mammalian cell culture plant commissioned to date by Lonza. At present, the total suite capacity amounts to 93’000 liters. Already underway is an addition of a 5’000 liter bioreactor to the existing facility. This reactor is expected to come on stream in mid-2008.
“The new facility in Portsmouth will further strengthen Lonza’s position as the leading supplier to the life-science industry. We will be able to offer our customers tailor-made solutions in manufacturing, with cutting edge fermentation technologies and new throughput-boosting downstream processing,” said Stephan Kutzer, Head of Lonza Biopharmaceuticals.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value added chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006 Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information:
Investor / Media Relations Lonza
Margot Connor
Tel +41 61 316 8253
Fax +41 61 316 9253
margot.connor@lonza.com
Media Relations Lonza German
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9253
dominik.werner@lonza.com
Investor Relations Lonza
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
